The problem of compliance to cholesterol altering therapy

被引:88
作者
Insull, W
机构
关键词
D O I
10.1046/j.1365-2796.1997.112133000.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This review's purpose is to describe for the practicing clinician the current knowledge about patient compliance to cholesterol-altering drugs and about procedures for compliance management applicable to clinical practice in the United States. Compliance is defined for four commonly measured major steps and, based on recent electronic monitoring data, for three quantitative categories of active medication-taking. The concepts and definition of compliance are undergoing evolutionary changes due to the measurement and availability of new dimensions through electronic monitoring of patient compliance. Substantial non-compliance to cholesterol-altering drugs has been reported in nine large clinical trials for primary and secondary prevention of coronary heart disease, in two HMOs, and, using electronic monitoring of compliance, in one clinical trial and a selected practice. The risks of treatment discontinuation increased continuously during treatment and totaled from 6 to 30% after 5 years. Patterns of day-to-day partial compliance are emerging. Procedures and knowledge for clinical management of compliance are described including methods of measuring compliance, risk factors for non-compliance, standards for compliance performance, epidemiology of compliance, procedures for managing compliance at the start of therapy and for addressing compliance problems during established treatment, simple office assessment of compliance by brief interview questions, compliance aids, prediction of compliance, and education and training of medical-care personnel in compliance management.
引用
收藏
页码:317 / 325
页数:9
相关论文
共 24 条
  • [1] DISCONTINUATION OF ANTIHYPERLIPIDEMIC DRUGS - DO RATES REPORTED IN CLINICAL-TRIALS REFLECT RATES IN PRIMARY-CARE SETTINGS
    ANDRADE, SE
    WALKER, AM
    GOTTLIEB, LK
    HOLLENBERG, NK
    TESTA, MA
    SAPERIA, GM
    PLATT, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) : 1125 - 1131
  • [2] [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
  • [3] EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA
    BRADFORD, RH
    SHEAR, CL
    CHREMOS, AN
    DUJOVNE, C
    DOWNTON, M
    FRANKLIN, FA
    GOULD, AL
    HESNEY, M
    HIGGINS, J
    HURLEY, DP
    LANGENDORFER, A
    NASH, DT
    POOL, JL
    SCHNAPER, H
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) : 43 - 49
  • [4] *CARE STUD GROUP, 1996, AM COL CARD ORL MARC
  • [5] CRAMER J, 1991, PATIENT COMPLIANCE M
  • [6] Cramer J. A., 1991, Patient compliance in medical practice and clinical trials, P123
  • [7] DAVIS DE, 1994, PHYSICIAN LEARNER LI, P366
  • [8] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE
    FRICK, MH
    ELO, O
    HAAPA, K
    HEINONEN, OP
    HEINSALMI, P
    HELO, P
    HUTTUNEN, JK
    KAITANIEMI, P
    KOSKINEN, P
    MANNINEN, V
    MAENPAA, H
    MALKONEN, M
    MANTTARI, M
    NOROLA, S
    PASTERNACK, A
    PIKKARAINEN, J
    ROMO, M
    SJOBLOM, T
    NIKKILA, EA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) : 1237 - 1245
  • [9] ANTIHYPERTENSIVE MEDICATION-TAKING - INVESTIGATION OF A SIMPLE REGIMEN
    GUERRERO, D
    RUDD, P
    BRYANTKOSLING, C
    MIDDLETON, BF
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1993, 6 (07) : 586 - 592
  • [10] Haynes RB., 1979, Compliance in health care, P516